Combination therapy with ruxolitinib plus 5-azacytidine or continuous infusion of low dose cytarabine is feasible in patients with blast-phase myeloproliferative neoplasms

Br J Haematol. 2014 Dec;167(5):714-6. doi: 10.1111/bjh.13046. Epub 2014 Jul 22.

Authors

Anne Mwirigi¹, Sofia Galli, Clodagh Keohane, Kavita Raj, Deepti H Radia, Claire N Harrison, Donal P McLornan

Affiliation

¹ Guy's and St. Thomas' NHS Foundation Trust, London , UK.

PMID: 25048366
DOI: 10.1111/bjh.13046

No abstract available

Keywords: Janus Kinase inhibitors; blast phase; hypomethylating agents; myeloproliferative neoplasms.

Publication types

Case Reports
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Aged
Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
Azacitidine / administration & dosage
Blast Crisis / drug therapy*
Female
Hematologic Neoplasms / drug therapy*
Humans
Male
Myeloproliferative Disorders / drug therapy*
Nitriles
Pyrazoles / administration & dosage
Pyrimidines

Substances

Nitriles
Pyrazoles
Pyrimidines
ruxolitinib
Azacitidine